Thurston, Springer, Miller, Herd & Titak, Inc. Alkermes Plc. Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $558 Million
- Q1 2025
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Alkermes Plc. stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 50 shares of ALKS stock, worth $1,471. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50
Previous 50
-0.0%
Holding current value
$1,471
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
410Shares Held
177MCall Options Held
229KPut Options Held
436K-
Black Rock Inc. New York, NY29.1MShares$856 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$536 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.8MShares$347 Million0.05% of portfolio
-
State Street Corp Boston, MA8.02MShares$236 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.88MShares$203 Million3.72% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.83B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...